Corvus Pharmaceuticals (CRVS) Net Cash Flow Growth (1y) (2016 - 2026)
Corvus Pharmaceuticals (CRVS) Net Cash Flow Growth (1y) (2016 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-14,223.53% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Corvus Pharmaceuticals |
1.00 Bn |
766.75 Mn |
- |
1,049.64% |
| Date | Value |
|---|
| Mar 31, 2026 |
1,049.64% |
| Dec 31, 2025 |
-57.91% |
| Sep 30, 2025 |
-16.37% |
| Jun 30, 2025 |
142.17% |
| Mar 31, 2025 |
27.56% |
| Dec 31, 2024 |
154.24% |
| Sep 30, 2024 |
-181.63% |
| Jun 30, 2024 |
-1,051.55% |
| Mar 31, 2024 |
-47.33% |
| Dec 31, 2023 |
34.51% |
| Sep 30, 2023 |
420.06% |
| Jun 30, 2023 |
33.09% |
| Mar 31, 2023 |
89.05% |
| Dec 31, 2022 |
-29.55% |
| Sep 30, 2022 |
-129.07% |
| Jun 30, 2022 |
-121.60% |
| Mar 31, 2022 |
-211.69% |
| Dec 31, 2021 |
-35.29% |
| Sep 30, 2021 |
489.17% |
| Jun 30, 2021 |
590.45% |
